



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/767,018	
			Filing Date	January 29, 2004	
			First Named Inventor	Brent R. Stockwell	
			Art Unit	1643	
			Examiner Name	K. A. Canella	
Sheet	1	of	2	Attorney Docket Number	WIBL-P01-011

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AB	US-20040248221-A1	12-09-2004	Stockwell	
	AC	US-20030171316-A1	09-11-2003	Jupe	
	AD	US-20040096444-A1	05-20-2004	Pizzo et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BB	WO-02/099122	12-12-2002	Exelixis Inc et al.		
	BC	WO-2004/030615	04-15-2004	Genentech Inc et al.		
	BD	WO-04/055519	07-01-2004	Hoffmann La Roche et al.		
	BE	WO-99/21988	05-06-1999	Shanghai Second Medical Univer et al.		
	BF	WO-02/083143	10-24-2002	Tularik Inc et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CR2	ABDEL-ALIM, et al., "Synthesis and biological activities of 6-bromo-2,3-disubstituted-4-(3H)-quinazolinones," Indian Journal of Chemistry, 33(B):260-265 (1994).	
	CS2	ADAM, et al., "Comprehensive Proteomic Analysis of Breast Cancer Cell Membranes Reveals Unique Proteins with Potential Roles in Clinical Cancer," JBC Papers in Press, 1-60 (2002).	
	CT2	AGER, et al., "Synthesis and Central Nervous System Activity of Quinazolones Related to 2-Methyl-3-(o-tolyl)-4(3H)-quinazoline (Methaqualone)," J. Med. Chem., 20(3):379-386 (1977).	
	CU2	Database Registry Chemical Abstracts Service, Columbus, Ohio, US; (2001-05-21), XP002405284, RN 336853-04-4.	
	CV2	Database Registry Chemical Abstracts Service, Columbus, Ohio, US; (2001-05-21), XP002405285, RN 336813-90-2.	
	CW2	DOLMA, et al., "Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells," Cancer Cell, 3:285-296 (2003).	
	CX2	FIGYS, et al., "VDAC Can Control Apoptosis By Controlling Metabolism," Biophysical Jr., 86(1):463A-464A (2004).	
	CY2	GUPTA, et al., "A Novel Class of Hypoglycaemic Agents: Syntheses & SAR in 2-Substituted 4(3H)-Quinazolones, 2-Substituted 4-Hydroxypolymethylene[5,6]pyrimidines & 3-Substituted 4-Oxo-pyrido[1,2- α]pyrimidines," Indian Journal of Chemistry, 9:201-206 (1971).	
	CZ2	IKONEN, et al., "Prohibitin, an antiproliferative protein, is localized to mitochondria," FEBS Letters, 358(3):273-277 (1995).	
	CA3	KOZHEVNIKOV, et al., "Synthesis in the 2-aminoethyl-3-(2'-tolyl)-4-quinazoline," Khimiko-	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/767,018
				Filing Date	January 29, 2004
				First Named Inventor	Brent R. Stockwell
				Art Unit	1643
				Examiner Name	K. A. Canella
Sheet	2	of	2	Attorney Docket Number	WIBL-P01-011

		Farmatsevticheskii Zhurnal, 4(11):22-25 (1970).	
	CB3	TANI, et al., "Studies on Biologically Active Halogenated Compounds II. Chemical Modifications of 6-amino-2-fluoromethyl-3-(o-toly)-4(3H) quinazolinone and the CNS depressant activities of related compounds," Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan, 27(11):2675-2687 (1979).	
	CC3	VERMA, et al., "A New Potent Anti-Inflammatory Quinazalone," Pharmacological Research Communications, Italian Pharmacological Society, IT, 13(10):967-979 (1981).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--